VAXCYTE, INC. Foreign Currency Transaction Gain (Loss), before Tax
VAXCYTE, INC. (PCVX) reported Foreign Currency Transaction Gain (Loss), before Tax of $8.45 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-05.
Financial Statements › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2024-11-05
- VAXCYTE, INC. foreign currency transaction gain (loss), before tax for the quarter ending 2024-09-30 was $8.45M, a 3622.47% increase year-over-year.
- VAXCYTE, INC. foreign currency transaction gain (loss), before tax for the quarter ending 2024-06-30 was $44.00K.
- VAXCYTE, INC. foreign currency transaction gain (loss), before tax for the quarter ending 2024-03-31 was -$2.36M.
- VAXCYTE, INC. foreign currency transaction gain (loss), before tax for the quarter ending 2023-12-31 was -$1.70M, a 268.38% decline year-over-year.
- VAXCYTE, INC. foreign currency transaction gain (loss), before tax for fiscal 2023 was -$1.90M.
- VAXCYTE, INC. foreign currency transaction gain (loss), before tax for fiscal 2022 was -$1.47M, a 188.08% decline from fiscal 2021.
- VAXCYTE, INC. foreign currency transaction gain (loss), before tax for fiscal 2021 was $1.67M.
- VAXCYTE, INC. foreign currency transaction gain (loss), before tax for fiscal 2020 was -$2.35M.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 3 month | Foreign Currency Transaction Gain (Loss), before Tax 6 month | Foreign Currency Transaction Gain (Loss), before Tax 9 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month |
|---|---|---|---|---|
| 2024-09-30 | $8.45M 10-Q · filed 2024-11-05 | $8.49M derived: sum of 2 quarters · filed 2024-11-05 | $6.13M 10-Q · filed 2024-11-05 | $4.43M derived: sum of 4 quarters · filed 2024-11-05 |
| 2024-06-30 | $44.00K 10-Q · filed 2024-08-06 | -$2.32M 10-Q · filed 2024-08-06 | -$4.02M derived: sum of 3 quarters · filed 2024-08-06 | -$3.79M derived: sum of 4 quarters · filed 2024-11-05 |
| 2024-03-31 | -$2.36M 10-Q · filed 2024-05-08 | -$4.06M derived: sum of 2 quarters · filed 2024-05-08 | -$3.83M derived: sum of 3 quarters · filed 2024-11-05 | -$3.94M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-12-31 | -$1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$1.47M derived: sum of 2 quarters · filed 2024-11-05 | -$1.58M derived: sum of 3 quarters · filed 2024-11-05 | -$1.90M 10-K · filed 2024-02-27 |
| 2023-09-30 | $227.00K 10-Q · filed 2024-11-05 | $120.00K derived: sum of 2 quarters · filed 2024-11-05 | -$198.00K 10-Q · filed 2024-11-05 | $812.00K derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | -$107.00K 10-Q · filed 2024-08-06 | -$426.00K 10-Q · filed 2024-08-06 | $585.00K derived: sum of 3 quarters · filed 2024-08-06 | -$102.00K derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$317.00K 10-Q · filed 2024-05-08 | $692.00K derived: sum of 2 quarters · filed 2024-05-08 | $5.00K derived: sum of 3 quarters · filed 2024-05-08 | -$1.73M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $322.00K derived: sum of 2 quarters · filed 2024-02-27 | -$1.41M derived: sum of 3 quarters · filed 2024-02-27 | -$1.47M 10-K · filed 2024-02-27 |
| 2022-09-30 | -$687.00K 10-Q · filed 2023-11-06 | -$2.42M derived: sum of 2 quarters · filed 2023-11-06 | -$2.48M 10-Q · filed 2023-11-06 | -$2.14M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$1.73M 10-Q · filed 2023-08-08 | -$1.79M 10-Q · filed 2023-08-08 | -$1.45M derived: sum of 3 quarters · filed 2024-02-27 | -$1.50M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $6.00K 10-Q · filed 2023-05-08 | $282.00K derived: sum of 2 quarters · filed 2024-02-27 | $228.00K derived: sum of 3 quarters · filed 2024-02-27 | -$186.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $276.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $222.00K derived: sum of 2 quarters · filed 2024-02-27 | -$192.00K derived: sum of 3 quarters · filed 2024-02-27 | $1.67M 10-K · filed 2024-02-27 |
| 2021-09-30 | -$54.00K 10-Q · filed 2022-11-07 | -$468.00K derived: sum of 2 quarters · filed 2022-11-07 | $1.39M 10-Q · filed 2022-11-07 | -$248.00K derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | -$414.00K 10-Q · filed 2022-08-08 | $1.45M 10-Q · filed 2022-08-08 | -$194.00K derived: sum of 3 quarters · filed 2023-02-27 | -$724.00K derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $1.86M 10-Q · filed 2022-05-09 | $220.00K derived: sum of 2 quarters · filed 2023-02-27 | -$310.00K derived: sum of 3 quarters · filed 2023-02-27 | -$486.00K derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | -$1.64M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$2.17M derived: sum of 2 quarters · filed 2023-02-27 | -$2.35M derived: sum of 3 quarters · filed 2023-02-27 | -$2.35M 10-K · filed 2023-02-27 |
| 2020-09-30 | -$530.00K 10-Q · filed 2021-11-10 | -$706.00K derived: sum of 2 quarters · filed 2021-11-10 | -$709.00K 10-Q · filed 2021-11-10 | -$427.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$176.00K 10-Q · filed 2021-08-11 | -$179.00K 10-Q · filed 2021-08-11 | $103.00K derived: sum of 3 quarters · filed 2022-02-28 | -$83.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$3.00K 10-Q · filed 2021-05-11 | $279.00K derived: sum of 2 quarters · filed 2022-02-28 | $93.00K derived: sum of 3 quarters · filed 2022-02-28 | $40.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $282.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $96.00K derived: sum of 2 quarters · filed 2022-02-28 | $43.00K derived: sum of 3 quarters · filed 2022-02-28 | -$135.00K 10-K · filed 2022-02-28 |
| 2019-09-30 | -$186.00K 10-Q · filed 2020-11-12 | -$239.00K derived: sum of 2 quarters · filed 2020-11-12 | -$417.00K 10-Q · filed 2020-11-12 | |
| 2019-06-30 | -$53.00K 10-Q · filed 2020-08-12 | -$231.00K 10-Q · filed 2020-08-12 | ||
| 2018-12-31 | $42.00K 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |